^
BCL2 overexpression
Diffuse Large B Cell Lymphoma
R-CHOP
Resistant: C3 – Early Trials
Mod Pathol - 2 weeks
No biomarker
Diffuse Large B Cell Lymphoma
EZM0414
Sensitive: B - Late Trials
Epizyme Press Release - 3 weeks
BTK expression + BCL2 expression
Diffuse Large B Cell Lymphoma
R-CHOP
Resistant: C3 – Early Trials
Anticancer Res - 3 weeks
BTK expression + BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
R-CHOP
Resistant: C3 – Early Trials
Anticancer Res - 3 weeks
BTK expression + MYC expression
Diffuse Large B Cell Lymphoma
R-CHOP
Resistant: C3 – Early Trials
Anticancer Res - 3 weeks
TP53 mutation
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
BRCA mutation
Diffuse Large B Cell Lymphoma
loncastuximab tesirine
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
No biomarker
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
No biomarker
Mediastinal B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
rituximab
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
tisagenlecleucel-T
Sensitive: A1 - Approval
CD20 positive
Diffuse Large B Cell Lymphoma
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
CD20 positive
Diffuse Large B Cell Lymphoma
Truxima (rituximab biosimilar)
Sensitive: A1 - Approval
CD20 positive
Diffuse Large B Cell Lymphoma
Ruxience (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
rituximab + polatuzumab vedotin
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
lenalidomide + tafasitamab
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
loncastuximab tesirine
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
selinexor
Sensitive: A1 - Approval
No biomarker
Mediastinal B Cell Lymphoma
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
rituximab/hyaluronidase
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
polatuzumab vedotin
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
brentuximab vedotin
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
rituximab + lenalidomide
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
lenalidomide
Sensitive: A2 - Guideline
No biomarker
Mediastinal B Cell Lymphoma
rituximab
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
ibrutinib
Sensitive: A2 - Guideline
TNFRSF8 positive
Diffuse Large B Cell Lymphoma
brentuximab vedotin
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
MINE
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
R-GemOx
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
GemOx
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
ESHAP
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
ICE
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
RICE
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
carboplatin + rituximab + gemcitabine + dexamethasone
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
carboplatin + gemcitabine + dexamethasone
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
GDP
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
RGDP
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
DHAX
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
DHAP
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
R-DHAP
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
EPOCH-R
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
R-CHOP
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
CEOP
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
CEPP
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
R-ESHAP
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
R-GCVP
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
R-CEOP
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
R-CEPP
Sensitive: A2 - Guideline
No biomarker
Diffuse Large B Cell Lymphoma
R-CDOP
Sensitive: A2 - Guideline
MYC rearrangement + BCL6 rearrangement
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A2 - Guideline
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A2 - Guideline
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A2 - Guideline
No biomarker
Mediastinal B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A2 - Guideline
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
ibrutinib
Sensitive: B - Late Trials
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
lenalidomide
Sensitive: B - Late Trials
MYC rearrangement
Diffuse Large B Cell Lymphoma
lenalidomide
Sensitive: B - Late Trials
LDH elevation
Diffuse Large B Cell Lymphoma
lenalidomide
Sensitive: B - Late Trials
No biomarker
Diffuse Large B Cell Lymphoma
ALLO-501A
Sensitive: B - Late Trials
EZH2 mutation
Diffuse Large B Cell Lymphoma
tazemetostat
Sensitive: C1 - Off-label
CD20 positive
Diffuse Large B Cell Lymphoma
rituximab
Sensitive: C1 - Off-label
BCL2 expression
Diffuse Large B Cell Lymphoma
venetoclax + obinutuzumab
Sensitive: C2 – Inclusion Criteria
CD79B mutation
Diffuse Large B Cell Lymphoma
ibrutinib
Sensitive: C2 – Inclusion Criteria
MYC expression
Diffuse Large B Cell Lymphoma
RG6146
Sensitive: C2 – Inclusion Criteria
BIRC5 expression
Diffuse Large B Cell Lymphoma
pembrolizumab + maveropepimut-S
Sensitive: C2 – Inclusion Criteria
MYC rearrangement
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: C2 – Inclusion Criteria
BCL6 rearrangement
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: C2 – Inclusion Criteria
CD20 positive
Diffuse Large B Cell Lymphoma
GEN3013
Sensitive: C2 – Inclusion Criteria
CD79B mutation
Diffuse Large B Cell Lymphoma
zanubrutinib
Sensitive: C2 – Inclusion Criteria
BCL2 rearrangement
Diffuse Large B Cell Lymphoma
rituximab
Sensitive: C2 – Inclusion Criteria
TNFRSF8 expression
Diffuse Large B Cell Lymphoma
rituximab + brentuximab vedotin
Sensitive: C2 – Inclusion Criteria
MYC overexpression
Diffuse Large B Cell Lymphoma
tisagenlecleucel-T
Resistant: C3 – Early Trials
MYC negative
Diffuse Large B Cell Lymphoma
tisagenlecleucel-T
Sensitive: C3 – Early Trials
MYC positive
Diffuse Large B Cell Lymphoma
tisagenlecleucel-T
Sensitive: C3 – Early Trials
MAD2L2 overexpression
Diffuse Large B Cell Lymphoma
rituximab
Resistant: C3 – Early Trials
CRTAM overexpression
Diffuse Large B Cell Lymphoma
nivolumab + ibrutinib
Sensitive: C3 – Early Trials
BTLA overexpression
Diffuse Large B Cell Lymphoma
nivolumab + ibrutinib
Sensitive: C3 – Early Trials
LEF1 overexpression
Diffuse Large B Cell Lymphoma
nivolumab + ibrutinib
Sensitive: C3 – Early Trials
KLHL14 mutation
Diffuse Large B Cell Lymphoma
nivolumab + ibrutinib
Sensitive: C3 – Early Trials
LRP1B mutation
Diffuse Large B Cell Lymphoma
nivolumab + ibrutinib
Sensitive: C3 – Early Trials
PD-L1 overexpression
Diffuse Large B Cell Lymphoma
nivolumab + ibrutinib
Sensitive: C3 – Early Trials
BCL2 positive
Diffuse Large B Cell Lymphoma
methotrexate
Sensitive: C3 – Early Trials
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
cytarabine + methotrexate
Resistant: C3 – Early Trials
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
methotrexate
Resistant: C3 – Early Trials
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
cytarabine + methotrexate
Resistant: C3 – Early Trials
BCL2 rearrangement
Diffuse Large B Cell Lymphoma
EPOCH-R
Sensitive: C3 – Early Trials
LDH elevation
Diffuse Large B Cell Lymphoma
ViPOR
Sensitive: C3 – Early Trials
BCL6 translocation
Diffuse Large B Cell Lymphoma
R-CHOP
Sensitive: C3 – Early Trials
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
R-CHOP
Resistant: C3 – Early Trials
MYC translocation + BCL2 translocation
Diffuse Large B Cell Lymphoma
R-CHOP
Sensitive: C3 – Early Trials
MYC translocation + BCL6 translocation
Diffuse Large B Cell Lymphoma
R-CHOP
Sensitive: C3 – Early Trials
MYC positive + BCL2 positive
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: C3 – Early Trials
MYC positive + BCL2 positive + BCL6 positive
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: C3 – Early Trials
BCL2 amplification
Diffuse Large B Cell Lymphoma
R-CHOP
Resistant: C3 – Early Trials
BCL2 positive
Diffuse Large B Cell Lymphoma
venetoclax
Sensitive: C3 – Early Trials
CD20 overexpression
Diffuse Large B Cell Lymphoma
R-CHOP
Sensitive: C3 – Early Trials
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: C3 – Early Trials
CD34 underexpression
Diffuse Large B Cell Lymphoma
R-CHOP
Sensitive: C3 – Early Trials
MYD88 L265P + CD79B mutation
Diffuse Large B Cell Lymphoma
R-CHOP
Sensitive: C3 – Early Trials